methyl 4-(p-bromomethylphenyl)-4-oxo-butanoate | 119152-42-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: methyl 4-(p-bromomethylphenyl)-4-oxo-butanoate
• 英文别名: methyl 4-[4-(bromomethyl)phenyl]-4-oxobutanoate
• CAS: 119152-42-0
• 化学式: C₁₂H₁₃BrO₃
• 分子量: 285.137
• InChiKey: XQLRARCDMCIVSD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 4-(p-bromomethylphenyl)-4-oxo-butanoate 在 盐酸 、 18-冠醚-6 、 potassium carbonate 、 锌 作用下， 以 甲苯 为溶剂， 生成
  参考文献：
  名称：

  Fluorescent stilbene, diene and triene surfactants as probes of reactivity in amylose inclusion complexes

  摘要：

  DOI：

  10.1016/s0040-4020(01)90263-7
• 作为产物：
  描述：

  4-(4-甲基苯基)-4-氧代丁酸甲酯 在 N-溴代丁二酰亚胺(NBS) 作用下， 生成 methyl 4-(p-bromomethylphenyl)-4-oxo-butanoate
  参考文献：
  名称：

  Hydrophobic-hydrophilic interactions in sodium dodecyl sulfate micelles. Stilbene-viologen complex formation as a probe of the micelle interior

  摘要：

  DOI：

  10.1021/ja00401a053

文献信息

• [EN] N-(4-(PIPERAZIN-1-YL)-PHENYL-2-OXAZOLIDINONE-5-CARBOXAMIDE DERIVATES AND RELATED COMPOUNDS AS ANTIBACTERIAL AGENTS<br/>[FR] DERIVES DE N-(4-(PIPERAZINE-1-YL)-PHENYL-2-OXAZOLIDINONE-5-CARBOXAMIDES ET COMPOSES ASSOCIES SERVANT D'AGENTS ANTIBACTERIENS
  申请人：UPJOHN CO

  公开号：WO2004045616A1

  公开（公告）日：2004-06-03

  The present invention provides antibacterial agents having the formula I described herein. or-pharmaceutically acceptable salts thereof wherein: A is a structure i, ii, iii, or iv, W is N(H)C(X)-R,. Het, or -Y HET, in which the Hot or Y HET is optionally substituted with =S or '0, provided that when A is structure iv, W is not - Y--1-MT or Het;

  本发明提供了具有以下式I的抗菌剂，或其药学上可接受的盐，其中：A是结构i、ii、iii或iv，W是N(H)C(X)-R、Het或-Y HET，在其中Hot或Y HET可以选择地被=S或'0取代，但当A是结构iv时，W不是-Y--1-MT或Het。
• Amine derivative
  申请人：Ishihara Yuji

  公开号：US20060128690A1

  公开（公告）日：2006-06-15

  The present invention provides a compound represented by the formula wherein Ar 1 is a cyclic group optionally having substituent(s); R is a hydrogen atom, an optionally halogenated C 1-6 alkyl, a phenyl optionally having substituent(s) or a pyridyl optionally having substituent(s); Ra 1 , Ra 2 , Ra 3 and Ra 4 are the same or different and each is a hydrogen atom, an optionally halogenated C 1-6 alkyl or the like; Ar is a monocyclic aromatic ring optionally having substituent(s); Y is an optionally halogenated alkylene group; and R 1 and R 2 are (1) the same or different and each is a hydrogen atom or a C 1-6 alkyl, (2) R 1 and R 2 form a nitrogen-containing heterocycle optionally having substituent(s) together with the adjacent nitrogen atom, or (3) R 1 and Y form a nitrogen-containing heterocycle optionally having substituent(s) together with the adjacent nitrogen atom, and R 2 is a hydrogen atom or a C 1-6 alkyl; provided that when the nitrogen-containing heterocycle formed by R 1 and R 2 together with the adjacent nitrogen atom is a piperazine, or when R is a C 1-4 alkyl, Ar 1 is a cyclic group having substituent(s), or a salt thereof, having a melanin-concentrating hormone antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like.

  本发明提供了一种化合物，其表示为式子： 其中，Ar1是一个环状基团，可以具有取代基；R是氢原子，可选卤代的C1-6烷基，苯环，可以具有取代基，或者吡啶环，可以具有取代基；Ra1，Ra2，Ra3和Ra4相同或不同，每个都是氢原子，可选卤代的C1-6烷基或类似物；Ar是一个单环芳香环，可以具有取代基；Y是可选卤代的脂肪族烷基；R1和R2是（1）相同或不同，每个都是氢原子或C1-6烷基，（2）R1和R2与相邻的氮原子一起形成含氮杂环，可以具有取代基，或（3）R1和Y与相邻的氮原子一起形成含氮杂环，可以具有取代基，并且R2是氢原子或C1-6烷基；但是当R1和R2与相邻的氮原子一起形成哌嗪环，或当R是C1-4烷基，Ar1是具有取代基的环状基团或其盐时，该化合物具有黑色素浓集激素拮抗作用，可用作预防或治疗肥胖症等药物。
• AMINE DERIVATIVE
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1593667A1

  公开（公告）日：2005-11-09

  The present invention provides a compound represented by the formula wherein Ar1 is a cyclic group optionally having substituent(s); R is a hydrogen atom, an optionally halogenated C1-6 alkyl, a phenyl optionally having substituent(s) or a pyridyl optionally having substituent(s); Ra1, Ra2, Ra3 and Ra4 are the same or different and each is a hydrogen atom, an optionally halogenated C1-6 alkyl or the like; Ar is a monocyclic aromatic ring optionally having substituent(s); Y is an optionally halogenated alkylene group; and R1 and R2 are (1) the same or different and each is a hydrogen atom or a C1-6 alkyl, (2) R1 and R2 form a nitrogen-containing heterocycle optionally having substituent(s) together with the adjacent nitrogen atom, or (3) R1 and Y form a nitrogen-containing heterocycle optionally having substituent(s) together with the adjacent nitrogen atom, and R2 is a hydrogen atom or a C1-6 alkyl; provided that when the nitrogen-containing heterocycle formed by R1 and R2 together with the adjacent nitrogen atom is a piperazine, or when R is a C1-4 alkyl, Ar1 is a cyclic group having substituent(s), or a salt thereof, having a melanin-concentrating hormone antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like.

  本发明提供了一种由式表示的化合物 其中 Ar1 是任选具有取代基的环状基团； R 是氢原子、任选卤化的 C1-6 烷基、任选具有取代基的苯基或任选具有取代基的吡啶基； Ra1、Ra2、Ra3 和 Ra4 相同或不同，各自为氢原子、任选卤代的 C1-6 烷基或类似物； Ar 是单环芳香环，可选择具有取代基； Y 是任选卤代亚烷基；以及 R1 和 R2 (1) 相同或不同，且各自为氢原子或 C1-6 烷基；(2) R1 和 R2 组成含氮杂环，可选择与相邻氮原子一起具有取代基；或 (3) R1 和 Y 组成含氮杂环，可选择与相邻氮原子一起具有取代基，且 R2 为氢原子或 C1-6 烷基； 条件是当 R1 和 R2 与相邻氮原子一起形成的含氮杂环是哌嗪时，或当 R 是 C1-4 烷基时，Ar1 是具有取代基的环状基团或其盐，具有黑色素浓缩激素拮抗作用，可用作预防或治疗肥胖症等的药物。
• Self-Assembly of Styrylthiophene Amphiphiles in Aqueous Dispersions and Interfacial Films:  Aggregate Structure, Assembly Properties, Photochemistry, and Photophysics
  作者：Xuedong Song、Jerry Perlstein、David G. Whitten

  DOI：10.1021/jp973421k

  日期：1998.7.1

  Fatty acids and phosphatidyl choline derivatives incorporating the photoreactive trans-styrylthiophene chromophore have been prepared and studied in Langmuir-Blodgett films and aqueous dispersions, respectively. Both absorption and fluorescence spectra in the assemblies show prominent shifts indicative of aggregation similar to that observed with similar trans-stilbene and ti-ans-azobenzene derivatives previously investigated. Studies of aqueous dispersions of the pure styrylthiophene phospholipids indicate the formation of structures much larger than the typical small unilamellar bilayer vesicles formed from saturated phospholipids of comparable chain length. Studies of the disaggregation process for two of the phospholipids give aggregation numbers of approximately 2 and 6, corresponding to 4 and 12 styrylthiophene units per aggregate. The stability of these aggregates is very similar to those of corresponding stilbene aggregates, and on the basis of spectral similarities it seems reasonable to propose a "pinwheel" fraction of a glide or herringbone structure as the "unit aggregate" and predominate species present in the aqueous dispersions. However, the chief photoreaction observed for the aqueous dispersions of the phospholipids is dimerization to form the syn head-to-head dimer, consistent with topologically controlled reaction from a translation structure in which nearest-neighbor chromophores are aligned parallel. Simulations suggest that while a translation layer structure may be of lowest energy, glide layer structures that show good agreement between measured and predicted properties are also energetically accessible. A possible explanation for the observed reactivity and photophysics is that within the aqueous dispersions there may be equilibration between "glide" and "translation" structures. When mixtures of the styrylthiophene phospholipids and saturated phospholipids are codispersed, bilayer vesicles are formed that are capable of entrapping reagents such as carboxyfluorescein. irradiation of the aggregated trans-styrylthiophene in these vesicles leads to release of the entrapped carboxyfluorescein concurrent with photodimerization of the styrylthiophene. The pattern of reagent release is similar to that observed upon photoisomerization of the corresponding azobenzene aggregates and suggests a "catastrophic" destruction of the vesicles.
• US7601868B2
  申请人：——

  公开号：US7601868B2

  公开（公告）日：2009-10-13